Clinical Trials Logo

Clinical Trial Summary

This study examines how marijuana use affects processes related to recovery from chronic posttraumatic stress disorder (PTSD). Half the participants will be individuals with chronic PTSD and heavy marijuana use and half will be individuals with chronic PTSD and no marijuana use. This study will assess how individuals with PTSD with heavy or no marijuana use perform on a discriminative conditioning and extinction paradigm designed to measure fear extinction learning, and how they respond to a brief daily imaginal exposure treatment in regards to PTSD symptom reduction.


Clinical Trial Description

In this study, 36 patients with chronic PTSD and heavy marijuana use (heavy) and 36 patients with chronic PTSD and no marijuana use (no use) will be recruited to examine the effects of marijuana use on behavioral (emotional experiencing), physiological (skin conductance, acoustic startle) and biological (cortisol, blood pressure) responding on a well-established discriminative conditioning and extinction paradigm. To examine real world therapeutic implications, we will also examine how individuals with PTSD and heavy or no marijuana use differentially respond to a brief (6 session, 50 min) daily imaginal exposure (IE) treatment. Throughout treatment, we will monitor level of cannabis metabolites in urine samples of marijuana users to correlate effects to outcomes and preliminarily explore how varying levels of cannabis metabolites affect extinction processes. Independent evaluators will assess patients at baseline, 4 weeks, and 12 weeks following study entry. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02874898
Study type Interventional
Source University of Washington
Contact
Status Completed
Phase N/A
Start date June 2016
Completion date August 15, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00158249 - Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals Phase 2
Completed NCT00842985 - Dronabinol Interactions in Humans N/A
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00218478 - Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1 Phase 1
Completed NCT00227864 - A Brief Marijuana Intervention for Adolescent Women - 1 Phase 3
Completed NCT00227903 - Therapeutic Substance Abuse Treatment in Pregnancy - 1 Phase 2
Completed NCT00249509 - Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals Phase 2
Completed NCT03717272 - Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects Phase 2
Completed NCT00142961 - Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Phase 2
Terminated NCT02102230 - CBT-I for Cannabis Use N/A
Completed NCT00580671 - Treatment for Adolescent Marijuana Abuse N/A
Completed NCT00360269 - Atomoxetine Treatment for ADHD and Marijuana Dependence Phase 2
Completed NCT00227916 - Motivational Interviews for Incarcerated Teens - 1 N/A
Completed NCT03154567 - Effects of Stress and Drug-cue Exposure (SCM) Phase 1
Active, not recruiting NCT05322941 - Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Phase 2
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT01762696 - A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth N/A
Completed NCT03154580 - Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users Phase 1
Completed NCT00142870 - Effectiveness of Bupropion in Treating Marijuana Dependent Individuals Phase 2